SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Resistance is the major cause of treatment failure and disease progression in non-small cell lung cancer (NSCLC). There is evidence that hypoxia is a key microenvironmental stress associated with resistance to cisplatin, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), and immunotherapy in solid NSCLCs. Numerous studies have contributed to delineating the mechanisms underlying drug resistance in NSCLC; nevertheless, the mechanisms involved in the resistance associated with hypoxia-induced molecular metabolic adaptations in the microenvironment of NSCLC remain unclear. Studies have highlighted the importance of posttranslational regulation of molecular mediators in the control of mitochondrial function in response to hypoxia-induced metabolic adaptations. Hypoxia can upregulate the expression of sirtuin 1 (SIRT1) in a hypoxia-inducible factor (HIF)-dependent manner. SIRT1 is a stress-dependent metabolic sensor that can deacetylate some key transcriptional factors in both metabolism dependent and independent metabolic pathways such as HIF-1α, peroxisome proliferator-activated receptor gamma (PPAR-γ), and PPAR-gamma coactivator 1-alpha (PGC-1α) to affect mitochondrial function and biogenesis, which has a role in hypoxia-induced chemoresistance in NSCLC. Moreover, SIRT1 and HIF-1α can regulate both innate and adaptive immune responses through metabolism-dependent and -independent ways. The objective of this review is to delineate a possible SIRT1/PGC-1α/PPAR-γ signaling-related molecular metabolic mechanism underlying hypoxia-induced chemotherapy resistance in the NSCLC microenvironment. Targeting hypoxia-related metabolic adaptation may be an attractive therapeutic strategy for overcoming chemoresistance in NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“However, little is known about the mechanisms of resistance associated with hypoxia-induced epigenetic changes and molecular metabolic flexibility in the microenvironment of drug-resistant NSCLC (25).”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740 · cited 1×
“In addition, metabolic properties of non-small-cell lung cancers can reprogram stromal cells to induce resistance to EGFR inhibitors (11, 20).”
BackgroundSt-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
HIF-1α pathway: role, regulation and intervention for cancer therapy
Masoud, G. N., & Li, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.05.007 · Cited by 1,871
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“Mitochondria are the main oxygen consumers at the crossroads of apoptotic pathways induced by anticancer agents, and excess mitochondrial activity leads to local hypoxia in the tumor microenvironment (Figure 3) (112, 113).”
BackgroundForkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580 · cited 1×
“FOXOs are involved in the regulation of apoptosis, the cell cycle, and DNA damage repair and their deacetylation by SIRT1 inhibits their transcriptional and biological activity (76, 77).”
BackgroundGomes, A. P., Price, N. L., Ling, A. J. Y., Moslehi, J. J., Montgomery, M. K., Rajman, L., White, J. P., Teodoro, J. S., Wrann, C. D., Hubbard, B. P., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.037 · Cited by 1,482
Cellular Adaptation to Hypoxia through Hypoxia Inducible Factors and beyond
Lee, P., Chandel, N. S., & Simon, M. C. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0227-y · Cited by 1,272 · cited 1×
“Responses to hypoxic stress involve cellular adaptations in protein synthesis, energy metabolism, mitochondrial respiration, and nutrient acquisition (110, 111).”
BackgroundHypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
SIRT1 Functionally Interacts with the Metabolic Regulator and Transcriptional Coactivator PGC-1α
Nemoto, S., Fergusson, M. M., & Finkel, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501485200 · Cited by 1,047
Cosse, J.-P., & Michiels, C. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008785914798 · Cited by 348 · cited 1×
“The hypoxic environment in solid tumors results from, among other factors, the rapid proliferation of tumor cells, leading to the depletion of available oxygen (21, 22).”
BackgroundSirtuin regulation in aging and injury
Poulose, N., & Raju, R. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.08.017 · Cited by 236 · cited 3×
“SIRT1 has been reported to regulate apoptotic, inflammatory, and oxidative stress-related processes in ischemia/hypoxia through the Frontiers in Oncology | www.frontiersin.org 5 deacetylation of its downstream targets, including P53, nuclear factor-kappa B (NF-kB), PGC-1a, forkhead box Os (FOXOs), and PPARs (71, 72).”
BackgroundYEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer
Mi, W., Guan, H., Lyu, J., Zhao, D., Xi, Y., Jiang, S., Andrews, F. H., Wang, X., Gagea, M., Wen, H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01173-4 · Cited by 159 · cited 1×
“The loss of homeostasis in the acetylation of histone and nonhistone proteins is closely related to tumor occurrence and development, and represents a potential target for cancer therapy (57, 58).”
BackgroundSelf-citationHypoxia increases sirtuin 1 expression in a hypoxia-inducible factor-dependent manner
Chen, R., Dioum, E. M., Hogg, R. T., Gerard, R. D., & Garcia, J. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175414 · Cited by 155 · cited 1×
“Extensive evidence supports that, under hypoxic conditions, SIRT1 overexpression stabilizes HIF-1a via direct binding and deacetylation, which may be a prerequisite for a consequent enhancement of cell invasion (103, 104).”
BackgroundHypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
Belisario, D. C., Kopecka, J., Pasino, M., Akman, M., De Smaele, E., Donadelli, M., & Riganti, C. (2020) · Cells · doi:10.3390/cells9122598 · Cited by 133 · cited 2×
“On the other hand, metabolic adaptations to hypoxia in tumor cells, such as altered genetic pathways and metabolic stress, can result in chemoresistance (53).”
Background
Cited by
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
(2024) · doi:10.7554/elife.87873.3 · Cited by 6
Islam, A., Chang, Y.-C., Chen, X.-C., Weng, C.-W., Chen, C.-Y., Wang, C.-W., Chen, M.-K., Tikhomirov, A. S., Shchekotikhin, A. E., & Chueh, P. J. (2023) · doi:10.1101/2023.03.29.534690
Islam, A., Chang, Y.-C., Chen, X.-C., Weng, C.-W., Chen, C.-Y., Wang, C.-W., Chen, M.-K., Tikhomirov, A. S., Shchekotikhin, A. E., & Chueh, P. J. (2024) · doi:10.7554/elife.87873.2
Metadata
- Authors
- Xu, R., Luo, X., Ye, X., Li, H., Liu, H., Du, Q., & Zhai, Q.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2021-07-26
- Volume
- 11
- Pages
- 682762-682762
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3185584194
- Cited by
- 47
- References
- 15
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.